USA

The approval strengthens Abbott’s position in the continuous glucose monitoring (CGM) market and expands its diagnostic capabilities beyond glucose-only tracking, which has traditionally defined wearable diabetes management tools.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.

The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.

Once completed, the acquisition will integrate SPR’s technology into Medtronic’s broader pain management strategy, allowing the company to offer additional options for patients and clinicians seeking alternatives to drug-based therapies.

Fujifilm Cellular Dynamics will use the expanded site to produce its iCell product portfolio, which plays a key role in new approach methods (NAMs) used in modern drug discovery and toxicity testing.

Health authorities have continued to emphasise coordinated cross-border surveillance, especially given the movement of populations between affected regions in DRC and Uganda.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

SmartIQ was developed in collaboration with leading cardiovascular centers to tackle one of the most persistent challenges in coronary imaging: balancing high-quality images with lower radiation exposure for both patients and healthcare professionals.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.